vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and PURE CYCLE CORP (PCYO). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $9.1M, roughly 1.2× PURE CYCLE CORP). PURE CYCLE CORP runs the higher net margin — 50.0% vs -186.0%, a 235.9% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 58.8%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 69.0%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

CCCC vs PCYO — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.2× larger
CCCC
$11.0M
$9.1M
PCYO
Growing faster (revenue YoY)
CCCC
CCCC
+54.0% gap
CCCC
112.8%
58.8%
PCYO
Higher net margin
PCYO
PCYO
235.9% more per $
PCYO
50.0%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
69.0%
PCYO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CCCC
CCCC
PCYO
PCYO
Revenue
$11.0M
$9.1M
Net Profit
$-20.5M
$4.6M
Gross Margin
68.4%
Operating Margin
-210.1%
48.0%
Net Margin
-186.0%
50.0%
Revenue YoY
112.8%
58.8%
Net Profit YoY
40.7%
16.0%
EPS (diluted)
$-0.09
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
PCYO
PCYO
Q4 25
$11.0M
$9.1M
Q3 25
$11.2M
$11.2M
Q2 25
$6.5M
$5.1M
Q1 25
$7.2M
$4.0M
Q4 24
$5.2M
$5.8M
Q3 24
$15.4M
$12.6M
Q2 24
$12.0M
$7.6M
Q1 24
$3.0M
$3.2M
Net Profit
CCCC
CCCC
PCYO
PCYO
Q4 25
$-20.5M
$4.6M
Q3 25
$-32.2M
$6.1M
Q2 25
$-26.0M
$2.3M
Q1 25
$-26.3M
$809.0K
Q4 24
$-34.6M
$3.9M
Q3 24
$-24.7M
$6.6M
Q2 24
$-17.7M
$2.8M
Q1 24
$-28.4M
$118.0K
Gross Margin
CCCC
CCCC
PCYO
PCYO
Q4 25
68.4%
Q3 25
67.7%
Q2 25
63.4%
Q1 25
38.2%
Q4 24
63.8%
Q3 24
77.8%
Q2 24
64.0%
Q1 24
55.6%
Operating Margin
CCCC
CCCC
PCYO
PCYO
Q4 25
-210.1%
48.0%
Q3 25
-306.4%
53.1%
Q2 25
-441.0%
26.0%
Q1 25
-402.9%
-33.2%
Q4 24
-728.4%
29.9%
Q3 24
-183.9%
62.0%
Q2 24
-178.6%
40.3%
Q1 24
-1060.2%
-11.5%
Net Margin
CCCC
CCCC
PCYO
PCYO
Q4 25
-186.0%
50.0%
Q3 25
-286.4%
54.5%
Q2 25
-402.6%
43.9%
Q1 25
-363.7%
20.3%
Q4 24
-667.8%
68.4%
Q3 24
-160.6%
52.6%
Q2 24
-147.6%
37.2%
Q1 24
-933.2%
3.7%
EPS (diluted)
CCCC
CCCC
PCYO
PCYO
Q4 25
$-0.09
$0.19
Q3 25
$-0.44
$0.26
Q2 25
$-0.37
$0.09
Q1 25
$-0.37
$0.03
Q4 24
$-0.50
$0.16
Q3 24
$-0.35
$0.27
Q2 24
$-0.26
$0.12
Q1 24
$-0.41
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
PCYO
PCYO
Cash + ST InvestmentsLiquidity on hand
$74.6M
$17.1M
Total DebtLower is stronger
$8.0M
Stockholders' EquityBook value
$256.6M
$147.5M
Total Assets
$359.1M
$168.1M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
PCYO
PCYO
Q4 25
$74.6M
$17.1M
Q3 25
$58.8M
$21.9M
Q2 25
$78.2M
$14.4M
Q1 25
$51.3M
$16.5M
Q4 24
$55.5M
$19.0M
Q3 24
$59.6M
$22.1M
Q2 24
$73.1M
$20.5M
Q1 24
$89.7M
$20.6M
Total Debt
CCCC
CCCC
PCYO
PCYO
Q4 25
$8.0M
Q3 25
$6.8M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$6.9M
Q3 24
$6.9M
Q2 24
Q1 24
Stockholders' Equity
CCCC
CCCC
PCYO
PCYO
Q4 25
$256.6M
$147.5M
Q3 25
$154.4M
$142.7M
Q2 25
$174.1M
$136.7M
Q1 25
$195.1M
$134.4M
Q4 24
$216.0M
$133.6M
Q3 24
$242.7M
$129.7M
Q2 24
$247.1M
$123.2M
Q1 24
$258.3M
$120.4M
Total Assets
CCCC
CCCC
PCYO
PCYO
Q4 25
$359.1M
$168.1M
Q3 25
$265.5M
$162.3M
Q2 25
$296.5M
$151.7M
Q1 25
$319.5M
$149.7M
Q4 24
$349.6M
$149.7M
Q3 24
$376.1M
$147.4M
Q2 24
$381.1M
$140.4M
Q1 24
$398.4M
$135.2M
Debt / Equity
CCCC
CCCC
PCYO
PCYO
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
PCYO
PCYO
Operating Cash FlowLast quarter
$-22.1M
$-979.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.21×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
PCYO
PCYO
Q4 25
$-22.1M
$-979.0K
Q3 25
$-31.2M
$9.4M
Q2 25
$-12.1M
$-503.0K
Q1 25
$-33.3M
$-1.4M
Q4 24
$-17.9M
$5.7M
Q3 24
$-24.1M
$3.1M
Q2 24
$-5.0M
$892.0K
Q1 24
$-18.1M
$-457.0K
Free Cash Flow
CCCC
CCCC
PCYO
PCYO
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
PCYO
PCYO
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
PCYO
PCYO
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%
Cash Conversion
CCCC
CCCC
PCYO
PCYO
Q4 25
-0.21×
Q3 25
1.53×
Q2 25
-0.22×
Q1 25
-1.70×
Q4 24
1.44×
Q3 24
0.47×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCCC
CCCC

Segment breakdown not available.

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

Related Comparisons